Meritage Portfolio Management’s Protara Therapeutics TARA Stock Holding History

Meritage Portfolio Management’s Portfolio TARA Stock Details TARA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-357	Closed	-$133K	–	199
2016 Q3	$133K	Hold	357	–	–	0.01%	177
2016 Q2	$115K	Hold	357	–	–	0.01%	188
2016 Q1	$111K	Hold	357	–	–	0.01%	172
2015 Q4	$222K	Hold	357	–	–	0.03%	191
2015 Q3	$199K	Hold	357	–	–	0.02%	195
2015 Q2	$255K	Buy	+357	New	+$221K	0.03%	198

Other funds holding TARA

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

DVC

Deer VII & Co Larchmont, New York $317M AUM 30.89% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

FCI

Financial Counselors Inc Overland Park, Kansas $70.9M AUM 16.78% 1-Year Est. Return

Meritage Portfolio Management's TARA Position: Q4 2016 in Review

Meritage Portfolio Management sold out of Protara Therapeutics (TARA) in Q4 2016, closing a stake of 357 shares — an estimated $133K sold.

Meritage Portfolio Management first reported a position in TARA in Q2 2015 and held it in 6 quarters. The position peaked at $255K in Q2 2015. 25 funds tracked by Wall St. Rank hold TARA as of Q4 2016.

Meritage Portfolio Management reported no remaining Protara Therapeutics position as of Q4 2016 after selling out during the quarter.
Meritage Portfolio Management sold 357 Protara Therapeutics shares in Q4 2016, an estimated $133K.
Meritage Portfolio Management first reported a position in Protara Therapeutics in Q2 2015 and held it in 6 quarters.
Meritage Portfolio Management's Protara Therapeutics position peaked at $255K in Q2 2015.
25 funds tracked by Wall St. Rank held Protara Therapeutics as of Q4 2016.

Based on Meritage Portfolio Management's 13F filing for Q4 2016, filed 24 Jan 2017.